CAI
Caris Life Sciences, Inc.
NasdaqGS Healthcare United States
32,57 $US
+4.69% today
+20.72% YTD · +3.30% 1Y
8
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
16
Hedge funds tracked
Latest available SEC 13F filings
75
/ 100
VERY STRONG

Analysis Caris Life Sciences, Inc. (CAI) — Kairos Score 75/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Key info

👔
CEO
Dr. David Dean Halbert M.D.
📍
HQ
750 West John Carpenter Freeway, Suite 800, Irving, TX, 75039, United States
👥
Employees
1 846
💰
Market cap
9 206 909 952,00 $US
📊
P/E
19.3
💸
Dividend yield
0.00%

🕴️ Insider activity (90 days)

8 transactions — 0 buys and 5 sales reported by Caris Life Sciences, Inc. executives.

DJ
Denton John Russel
See Remarks · 2026-09-22
Sell
BB
Brille Brian J
See Remarks · 2026-09-17
Other
BB
Brille Brian J
See Remarks · 2026-09-17
Sell

🏦 Hedge Funds

16 institutional funds report a position on CAI in their latest SEC quarterly filing.

FMR LLC
COATUE MANAGEMENT LLC
PointState Capital LP
JPMORGAN CHASE & CO
BlackRock, Inc.

📰 Recent news

15 recent articles on CAI.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as Caris Life Sciences, Inc.

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of CAI on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 8 insider transactions over 90 days
✅ All 16 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year